Artificial expression constructs for selectively modulating gene expression in selected neuronal cell populations

Abstract

To provide artificial expression constructs for selectively modulating gene expression in selected neuronal cell populations.SOLUTION: Artificial expression constructs can be used to selectively express synthetic genes or modify gene expression in GABAergic neurons generally; and / or GABAergic neuron cell types such as lysosomal associated membrane protein 5 (Lamp5) neurons; vasoactive intestinal polypeptide-expressing (Vip) neurons; somatostatin (Sst) neurons; and / or parvalbumin (Pvalb) neuron cell types. Certain artificial expression constructs additionally drive selective gene expression in Layer 4 and / or layer 5 intratelencephalic (IT) neurons, deep cerebellar nuclear neurons or cerebellar Purkinje cells.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 806,660, filed February 15, 2019, U.S. Provisional Patent Application No. 62 / 806,686, filed February 15, 2019, and U.S. Provisional Patent Application No. 62 / 874,859, filed July 16, 2019, each of which is incorporated by reference in its entirety as if fully set forth herein.

[0002] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT This invention was made with government support under grants MH114126 and DA036909 awarded by the National Institutes of Health. The government has certain rights in this invention.

[0003] The present disclosure provides artificial expression constructs for selectively modulating gene expression in selected central nervous system cell types. The artificial expression constructs can be used to selectively express synthetic genes or modify gene expression in gamma-aminobutyric acid (GABA)ergic neurons in general and / or GABAergic neuronal cell subclasses, such as lysosomal membrane protein 5 (Lamp5) neurons, vasoactive intestinal polypeptide-expressing (Vip) neurons, somatostatin (Sst) neurons, and / or parvalbumin (Pvalb) neurons. Certain artificial expression constructs also drive selective gene expression in layer 4 and / or layer 5 intratelencephalic (IT) neurons, or non-neocortical neurons, such as deep cerebellar nuclei Pvalb-positive neurons or cerebellar Purkinje cells. [Background technology]

[0004] To fully understand brain biology, different cell types must be distinguished and defined, and to study them further, artificial expression constructs must be identified that can selectively label and perturb them. In mice, recombinase driver lines have been used to great effect to label cell populations that share marker gene expression. Summary of the Invention [Problem to be solved by the invention]

[0005] However, the generation, maintenance, and use of such lines to label cell types with high specificity can be expensive and frequently requires triple transgenic crosses, which result in low numbers of experimental animals. Furthermore, these tools require germline transgenic animals and are therefore not applicable to humans. [Means for solving the problem]

[0006] The present disclosure provides artificial expression constructs that selectively drive gene expression in target central nervous system cell populations, including gamma-aminobutyric acid (GABA)ergic neurons in general and / or GABAergic neuronal cell subclasses, such as lysosomal membrane protein 5 (Lamp5) neurons, vasoactive intestinal polypeptide-expressing (Vip) neurons, somatostatin (Sst) neurons, and / or parvalbumin (Pvalb) neurons. Non-neocortical neurons, such as layer 4 and / or layer 5 intratelencephalic (IT) neurons, or deep cerebellar nuclei Pvalb-positive neurons or cerebellar Purkinje cells, can also be targeted for selective gene expression.

[0007] Certain embodiments of the artificial expression constructs utilize the following enhancers to selectively drive protein expression in targeted central nervous system cell populations (enhancer / target cell population): Grik1_enhGad2-1 / GABAergic neurons in general, Grik1_enhGad2-2 / GABAergic neurons in general, mscRE5 / GABAergic neurons in general, mscRE8 / GABAergic neurons in general, eHGT_019h / Lamp5 neurons, eHGT_022h / Lamp5 and Vip neurons, eHGT_022m / Lamp5 and Vip neurons. eHGT_017h / Lamp5, Vip and Sst neurons, eHGT_17m / Lamp5, Vip and Sst neurons, eHGT_079h / parvalbumin (Pvalb) neuron cell type, eHGT_082h / Pvalb neuron cell type in cortical and deep cerebellar nuclei neurons, eHGT_086h / Pvalb neuron cell type, eHGT_128h / Pvalb neuron cell type, eHGT_140h / Pvalb neuron cell type, eHGT_064h / Pvalb and Sst neuron cell types, eHGT_023h / Pvalb cell type, L4 and L5 IT neurons and Purkinje cells, and eHGT_359 / Pvalb cell type and cerebellar Purkinje cells.

[0008] Certain embodiments provide artificial expression constructs comprising features of the vectors described herein, including the vectors: AiP1146, AiP1113, AiP1147, AiP1147, AiP1013, AiP1012, CN1525, CN1528, CN1532, CN1621, CN1633, CN1259, CN2045, CN1255, CN1408, CN1258, CN1279, CN1253, and CN1274.

[0009] Some of the drawings presented herein are better understood in color. Applicant reserves the right to consider color versions of the drawings as part of the original submission and to present color images of the drawings in later proceedings. For example, Figures 3A, 3B, 5, 6A, 6B, 7A, 7B, 8A, 8B, 9A, 9C, 10A, 11A, 11B, 12A, 13A, 13B, 14A, 14B, 14D, 15A, 15B, 16A, 16B, 17A, 17B, 18A, 18B, 19A, 19B, 19C, and 20 described below reflect color-labeled assays presented as black-and-white images. [Brief explanation of the drawings]

[0010] [Figure 1] Overview of enhancer discovery for viral tools. To construct cell-type-specific labeling tools, we isolated cells from adult mouse cortex and performed single-cell assay of transposase-accessible chromatin using sequencing (scATAC-seq). Samples were clustered and compared with single-cell RNA sequencing (scRNA-seq) datasets to identify clusters. Next, single cells matching the same transcriptome type were pooled and the genomes were searched for type-specific putative enhancers. These regions were cloned upstream of a minimal promoter in the AAV genome backbone, which was used to generate self-complementary adeno-associated viral vectors (scAAV) or recombinant adeno-associated viral vectors (rAAV). These viral tools were delivered retroorbitally to label specific GABAergic neuronal populations. In cell-type-matched cells, enhancers recruit their cognate transcription factors to drive cell-type-specific expression. In other cells, the viral genome is present but no transcripts are expressed. [Figure 2A]vAi30.0 (AiP1146) with Grik1_enhGad2-1 enhancer. (2A) Schematic diagram of the enhancer-containing viral vector showing all major components: ITR = inverted terminal repeats, Hsp68 = heat shock protein 68 minimal promoter, WPRE3 = woodchuck posttranscriptional regulatory element 3, BGHpA = bovine growth hormone polyA, and Grik1_enhGad2-1 = eAi12.0 (MGT_E31) enhancer. [Figure 2B] vAi30.0 (AiP1146) carrying the Grik1_enhGad2-1 enhancer. (2B) Purified AiV1146 virus was injected into the primary visual cortex of Gad2-IRES-Cre Ai14 animals, and transgene expression was analyzed in fixed brain sections several weeks after injection. tdTomato labels a pan-GABAergic interneuron population. Co-labeling of EGFP and tdTomato was observed in many cells (see merge image), confirming that this virus labels a subset of GABAergic neurons. [Figure 3A] vAi30.1 (AiP1113) carrying the Grik1_enhGad2-1 enhancer. Purified AiV1113 virus was injected into the retro-orbital sinus of C57BL / 6J wild-type mice, and EGFP expression was analyzed in fixed brain sections 2 weeks after injection. (3A) Natural fluorescence and (3B) enhanced fluorescence stained with anti-GFP antibody are shown. GFP-positive labeled neurons were scattered throughout the cortex and displayed the typical aspiny dendritic morphology characteristic of cortical interneurons. [Figure 3B] vAi30.1 (AiP1113) carrying the Grik1_enhGad2-1 enhancer. Purified AiV1113 virus was injected into the retro-orbital sinus of C57BL / 6J wild-type mice, and EGFP expression was analyzed in fixed brain sections 2 weeks after injection. (3A) Natural fluorescence and (3B) enhanced fluorescence stained with anti-GFP antibody are shown. GFP-positive labeled neurons were scattered throughout the cortex and displayed the typical aspiny dendritic morphology characteristic of cortical interneurons. [Figure 4]vAi31.0 (AiP1147) carrying the Grik1_enhGad2-2 enhancer. Purified AiV1147 virus was injected into the primary visual cortex of Gad2-IRES-Cre mice. Ai14 animals and transgene expression was analyzed in fixed brain sections several weeks after injection. tdTomato labels a pan-GABAergic interneuron population. Co-labeling of EGFP and tdTomato was observed in many cells (see merge image), confirming that this virus labels a subset of GABAergic neurons. [Figure 5] vAi11.0 (AiP989) carrying the mscRE5 enhancer. Purified AiV989 virus was injected into the retro-orbital sinus of C57BL / 6J wild-type mice, and EGFP expression was analyzed in fixed brain sections 2 weeks after injection. GFP-positive neurons were observed scattered throughout the cortex and displayed the typical aspiny dendritic morphology characteristic of cortical interneurons. Labeled neurons with similar morphology were also observed in other subcortical brain structures. [Figure 6A] vAi12.0 (AiP1013) with the mscRE5 enhancer. (6A) Purified AiV1013 virus was injected into the retroorbital sinus of Ai65F mice (Ai65F mice are an Flp-dependent tdTomato reporter mouse strain), and tdTomato expression was analyzed in fixed brain sections 2 weeks after injection. [Figure 6B] vAi12.0 (AiP1013) containing the mscRE5 enhancer. (6B) Magnified image of the boxed area shown in Figure 6A. tdTomato-positive neurons were observed scattered throughout the cortex and displayed the typical aspiny dendritic morphology characteristic of cortical interneurons. Labeled neurons with both similar and diverse morphologies were also observed in many other subcortical brain structures. [Figure 7A] vAi14.0 (AiP1012) carrying the mscRE8 enhancer. (7A) Purified AiV1012 virus was injected into the retro-orbital sinus of Ai65F mice (Ai65F mice are an Flp-dependent tdTomato reporter mouse strain), and tdTomato expression was analyzed in fixed brain sections 2 weeks after injection. [Figure 7B]vAi14.0 (AiP1012) containing the mscRE8 enhancer. (7B) Magnified image of the boxed area shown in Figure 7A. tdTomato-positive neurons were observed scattered throughout the cortex and displayed the typical aspiny dendritic morphology characteristic of cortical interneurons. Labeled neurons with similar morphology were also observed in many other subcortical brain structures. [Figure 8A] (8A) Fluorescent expression of CN1525 (eHGT_019h) shown in black in a sagittal section of the whole mouse brain. [Figure 8B] (8B) Spontaneous SYFP2 fluorescence image of a raw section of V1 shows sparse cortical labeling. [Figure 8C] (8C) Single-cell transcriptome characterization of SYFP2 fluorescent cells isolated from mouse V1. After single-cell gene expression analysis, cells were mapped to an existing taxonomy of mouse V1 cell types. The plot shows single cells grouped by subtype. [Figure 8D] (8D) The dendrogram shows, where possible, the mapping of each single cell to the terminal branches of the mouse classification. The position of each circle reflects the extent of single cell mapping (terminal branch direction), and the size of the circle reflects the number of single cells mapped to that point in the hierarchy. The downward-projecting bar reflects the number of cells mapping to that terminal branch of the cell type classification. Note that the majority of cells are Lamp5+. [Figure 9A] (9A) Fluorescence (white) image of CN1258 (eHGT_022h) in a live section of mouse V1 shows sparse cortical labeling. [Figure 9B] (9B) Quantification of three replicates of the overlap between CN1258-driven SYFP2 expression and antibody markers of GABAergic neuron types Lamp5, Vip, Sst, and Pvalb. [Figure 9C] (9C) CN1258 labeling of ex vivo human organotypic slice tissue shows enrichment of SYFP2 in the upper layers of the neocortex, indicating enrichment of Lamp5 and VIP cells. [Figure 9D](9D) Single-cell transcriptome characterization of SYFP2-fluorescent cells isolated from human MTG (top) and mouse V1 (bottom). After single-cell gene expression analysis, cells were mapped to existing classifications of human MTG or mouse V1 cell types. The plot shows the mapping of each single cell to either classification, as described in connection with Figure 8D. Note that the majority of cells are Lamp5+ or Vip+ for both species. [Figure 10A] (10A) Fluorescence (white) image of CN1279 (eHGT_022m) in a live section of mouse V1 shows sparse cortical labeling. [Figure 10B] (10B) Quantification of three replicates of the overlap between CN1259-driven SYFP2 expression and antibody markers of GABAergic neuron types Lamp5, Vip, Sst, and Pvalb. [Figure 11A] (11A) Fluorescent expression of CN1253 (eHGT_017h) shown in black in a sagittal section of the whole mouse brain. [Figure 11B] (11B) High-resolution image showing overlap of SYFP2 fluorescence in CN1253 with mRNA expression of GABAergic markers Gad1, Sst, and Lamp5. Arrows indicate SYFP-labeled cells. [Figure 11C] (11C) Single-cell transcriptome characterization of SYFP2 fluorescent cells isolated from mouse V1. Following single-cell gene expression analysis, cells were mapped to the existing classification of mouse V1 cell types, as described in connection with Figure 8D. Note that the majority of cells are Lamp5+, Vip+, or Sst+. [Figure 12A] (12A) Fluorescent expression of CN1274 (eHGT_017m) shown in black in a sagittal section of the whole mouse brain. [Figure 12B] (12B) Single-cell transcriptome characterization of SYFP2 fluorescent cells isolated from mouse V1. After single-cell gene expression analysis, cells were mapped to the existing classification of mouse V1 cell types, as described in connection with Figure 8D. Note that the majority of cells are Lamp5+, Vip+, or Sst+. [Figure 13A](13A) Fluorescent expression of CN1525 (eHGT_079h) shown in black in a sagittal section of the whole mouse brain. [Figure 13B] (13B) High-resolution image showing overlap of SYFP2 fluorescence in CN1525 with mRNA expression of the GABAergic markers Gad1 and Pvalb. Arrows indicate SYFP2-labeled cells. [Figure 13C] (13C) Single-cell transcriptome characterization of SYFP2 fluorescent cells isolated from mouse V1. Following single-cell gene expression analysis, the cells were mapped to an existing classification of mouse V1 cell types, as described in relation to Figure 8D. Note that nearly all cells are Pvalb neuron types. [Figure 14A] (14A) Fluorescent expression of CN1528 (eHGT_082h) shown in black in a sagittal section of the whole mouse brain. [Figure 14B] (14B) High-resolution image showing overlap of SYFP2 fluorescence in CN1528 with mRNA expression of the GABAergic markers Gad1 and Pvalb. Arrows indicate SYFP2-labeled cells. Arrows highlight several SYFP2+ cells. [Figure 14C] (14C) Single-cell transcriptome characterization of SYFP2 fluorescent cells isolated from mouse V1. Following single-cell gene expression analysis, the cells were mapped to an existing classification of mouse V1 cell types, as described in relation to Figure 8D. Note that nearly all cells are Pvalb neuron types. [Figure 14D] (14D) Pvalb-positive glutamatergic (Gad1-negative) and GABAergic (Gad1-positive) cells in the deep cerebellar nuclei are labeled with SYFP2 after intravenous administration of CN1528 packaged by PHP.eB. [Figure 15A] (15A) Fluorescent expression of CN1532 (eHGT_086h) shown in black in a sagittal section of the whole mouse brain. [Figure 15B](15B) High-resolution image showing overlap of SYFP2 fluorescence in CN1532 with mRNA for the GABAergic markers Gad1 and Pvalb. Arrows indicate SYFP2-labeled cells. [Figure 16A] (16A) Fluorescent expression of CN1621 (eHGT_128h) shown in black in a sagittal section of the whole mouse brain. [Figure 16B] (16B) High-resolution image showing overlap of SYFP2 fluorescence in CN1621 with mRNA expression of the GABAergic marker Pvalb. Arrows indicate SYFP2-labeled cells. [Figure 16C] (16C) Single-cell transcriptome characterization of SYFP2 fluorescent cells isolated from mouse V1. Following single-cell gene expression analysis, the cells were mapped to an existing classification of mouse V1 cell types, as described in relation to Figure 8D. Note that nearly all cells are Pvalb neuron types. [Figure 17A] (17A) Fluorescent expression of CN1633 (eHGT_140h) shown in black in a sagittal section of the whole mouse brain. [Figure 17B] (17B) High-resolution image showing overlap of SYFP2 fluorescence in CN1633 with mRNA expression of the GABAergic markers Gad1 and Pvalb. Arrows indicate SYFP2-labeled cells. [Figure 17C] (17C) Single-cell transcriptome characterization of SYFP2 fluorescent cells isolated from mouse V1. Following single-cell gene expression analysis, the cells were mapped to an existing classification of mouse V1 cell types, as described in relation to Figure 8D. Note that nearly all cells are Pvalb neuron types. [Figure 18A] (18A) Fluorescent expression of CN1408 (eHGT_064) shown in black in a sagittal section of the whole mouse brain. [Figure 18B] (18B) High-resolution image showing overlap of SYFP2 fluorescence of CN1408 with mRNA expression of the GABAergic markers Pvalb or Sst. Arrows indicate SYFP2-labeled cells that colabel with Pvalb or Sst, and asterisks indicate labeled cells that are not colabeled with Pvalb or Sst. [Figure 18C] (18C) Single-cell transcriptome characterization of SYFP2-fluorescent cells isolated from mouse V1. Following single-cell gene expression analysis, cells were mapped to an existing classification of mouse V1 cell types, as described in connection with Figure 8D. Note that nearly all of the recovered cells were either Pvalb or Sst neuron types. [Figure 19A] (19A) Fluorescent expression of CN1259 (eHGT_023h) shown in black in a sagittal section of the whole mouse brain. Strong expression is observed in non-neocortical brain regions such as the neocortex and cerebellum. [Figure 19B] (19B) High-resolution images show overlap of SYFP2 fluorescence in CN1259 with mRNA expression of the GABAergic markers Gad1, Vip, and Pvalb. Arrows indicate SYFP2-labeled cells. Note the overlap of most cells with Gad1 and many with Pvalb. [Figure 19C] (19C) Pvalb-positive Purkinje cells (Gad1 and Pvalb-positive) in the cerebellum are labeled with SYFP2 after intravenous administration of CN1259 packaged in PHP.eB. [Figure 20] Fluorescent expression of CN2045 (eHGT_359h) shown in black in a sagittal section of a whole mouse brain. Expression in the cortex and hippocampus indicates expression of Pvalb, and there is strong labeling of cerebellar Purkinje cells. [Figure 21A-1] (21A) A table listing the components contained in each vector sequence to summarize the vector name and length, enhancer, promoter, product class, primary product, and other components of the vector. [Figure 21A-2] (21A) A table listing the components contained in each vector sequence to summarize the vector name and length, enhancer, promoter, product class, primary product, and other components of the vector. [Figure 21B-1](21B) Summarizes the cell-type specificity of enhancers and vectors. The species of origin is indicated, with H indicating human and M indicating mouse. Cell-type specificity is indicated, with S = a subset of types within the group and A = all types within the group. Validation methods are indicated by the following: * = tested and validated in mouse, RNA-seq, and another modality; ~ = tested and validated in mouse and primate / human, RNA-seq, and another modality; ^ = tested and validated in mouse using at least one validation method; and + = tested and awaiting additional validation. The column labeled Validation Method lists the validation method: T indicates validation by tissue expression; R indicates validation by single-cell RNA-seq; I indicates validation by immunohistochemistry or mFISH; and TG indicates validation by tissue expression and gene labeling. [Figure 21B-2] (21B) Summarizes the cell-type specificity of enhancers and vectors. The species of origin is indicated, with H indicating human and M indicating mouse. Cell-type specificity is indicated, with S = a subset of types within the group and A = all types within the group. Validation methods are indicated by the following: * = tested and validated in mouse, RNA-seq, and another modality; ~ = tested and validated in mouse and primate / human, RNA-seq, and another modality; ^ = tested and validated in mouse using at least one validation method; and + = tested and awaiting additional validation. The column labeled Validation Method lists the validation method: T indicates validation by tissue expression; R indicates validation by single-cell RNA-seq; I indicates validation by immunohistochemistry or mFISH; and TG indicates validation by tissue expression and gene labeling. [Figure 22-1]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-2]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-3]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-4]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-5]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-6]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-7]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-8]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-9]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-10]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-11]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-12]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-13]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-14]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-15]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-16]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-17]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-18]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-19]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-20]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-21]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-22]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-23]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-24]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-25]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-26]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-27]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-28]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-29]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-30]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-31]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-32]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-33]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-34]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-35]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-36]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-37]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-38]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-39]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-40]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-41]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-42]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-43]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-44]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-45]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-46]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). [Figure 22-47]Sequences supplementing the present disclosure include enhancer Grik1_enhGad2-1 (eAi12.0, MGT_E31) (SEQ ID NOs: 1 and 42), enhancer Grik1_enhGad2-2 (eAi13.0, MGT_E65) (SEQ ID NO: 2), enhancer mscRE5 (eAi4.0, MGT_E5) (SEQ ID NO: 3), enhancer mscRE8 (eAi5.0, MGT_E8) (SEQ ID NO: 4), enhancer eHGT_079h (eAi115.0) (SEQ ID NO: 5), enhancer eHGT_082h (eAi116.0) (SEQ ID NO: 6), enhancer eHGT_086h (eAi117.0) (SEQ ID NO: 7), enhancer e Enhancer eHGT_128h (eAi119.0) (SEQ ID NO: 8), enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), enhancer eHGT_359h (SEQ ID NO: 11), enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), mutated minCMV promoter (SacI RE site removed) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), optimized Flp recombinase (FlpO) (SEQ ID NO: 27), improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), exemplary plasmid backbone 1-left ITR (SEQ ID NO: 124), exemplary plasmid backbone 1-right ITR (SEQ ID NO: 125), exemplary plasmid backbone 2-left ITR (SEQ ID NO: 126), exemplary plasmid backbone 2-right ITR (SEQ ID NO: 127), PHP.eB capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989 vAi11.0,) (SEQ ID NO: 46), AiP1013 (TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012 (TG1012, vAi14.0) (SEQ ID NO: 48), CN1525 (vAi115.0) (SEQ ID NO: 49), CN1528 (vAi116.0) (SEQ ID NO: 50), CN1532 (vAi117.0) (SEQ ID NO: 51), CN1621 (vAi119.0) (SEQ ID NO: 52), CN1633 (vAi120.0) (SEQ ID NO: 53), CN1259 (vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), lactase (SEQ ID NO: 62), lipase (SEQ ID NO: 63), helicase (SEQ ID NO: 64), amylase (SEQ ID NO: 65), α-glucosidase (SEQ ID NO: 66), transcription factor SP1 (SEQ ID NO: 67), transcription factor AP-1 (SEQ ID NO: 68), heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 70), 44105 (SEQ ID NO: 71), transforming growth factor receptor beta 1 (SEQ ID NO: 72), platelet-derived growth factor receptor (SEQ ID NO: 73), epidermal growth factor receptor (SEQ ID NO: 74), vascular endothelial growth factor receptor (SEQ ID NO: 75), interleukin-8 receptor alpha (SEQ ID NO: 76), caveolin (SEQ ID NO: 77), dynamin (SEQ ID NO: 78), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 79), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 80), clathrin light chain A isoform a (SEQ ID NO: 81), clathrin light chain B isoform a (SEQ ID NO: 82), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 83), Ras-related protein Rab-11A, UniProtKB / Swiss-Prot: P62491.3: (SEQ ID NO: 84), platelet-derived growth factor (SEQ ID NO: 85), transforming growth factor-β3 (SEQ ID NO: 86), nerve growth factor (SEQ ID NO: 87), epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 90), protachykinin-1 (SEQ ID NO: 91), protachykinin-1 (SEQ ID NO: 92), oxytocin-neurophysin 1 (SEQ ID NO: 93), oxytocin at positions 20-28 of oxytocin-neurophysin 1 (SEQ ID NO: 94), somatostatin (SEQ ID NO: 95), myosin light chain kinase, green fluorescent protein, calmodulin chimera (chain A) (SEQ ID NO: 96), genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium indicator indicator (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channelrhodopsin 1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-associated protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease 4 (SEQ ID NO: 111), deoxyribonuclease II beta (SEQ ID NO: 112), sodium channel protein type 1 subunit alpha (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 115). DETAILED DESCRIPTION OF THE INVENTION

[0011] To fully understand brain biology, we need to distinguish and define various cell types, and to further study them, we need to identify artificial expression constructs that can selectively label and perturb them. (Tasic, Curr. Opin. Neurobiol. 50, 242-249 (2018); Zeng & Sanes, Nat. Rev. Neurosci. 18, 530-546 (2017)) In mice, recombinase driver lines have been used to great effect to label cell populations that share marker gene expression. (Daigle et al., Cell 174, 465-480.e22 (2018); Taniguchi et al., Neuron 71, 995-1013 (2011); Gong et al., J. Neurosci. 27, 9817-9823 (2007)) However, the generation, maintenance, and use of such lines to label cell types with high specificity can be expensive and frequently requires triple transgenic crosses, which result in low numbers of experimental animals. Furthermore, these tools require germline transgenic animals and are therefore not applicable to humans.

[0012] The present disclosure provides artificial expression constructs that selectively drive gene expression in target central nervous system cell populations, including gamma-aminobutyric acid (GABA)ergic neurons in general and / or GABAergic neuronal cell types, such as lysosomal membrane protein 5 (Lamp5) neurons, vasoactive intestinal polypeptide-expressing (Vip) neurons, somatostatin (Sst) neurons, and parvalbumin (Pvalb) neuronal cell types. Layer 4 (L4) and / or layer 5 (L5) intratelencephalic (IT) neurons, deep cerebellar nuclei neurons, or cerebellar Purkinje cells can also be targeted for selective gene expression.

[0013] Particular embodiments of the artificial expression constructs utilize the following enhancers to selectively drive gene expression in target central nervous system cell populations (enhancer / target cell population): Grik1_enhGad2-1 / GABAergic neurons in general, Grik1_enhGad2-2 / GABAergic neurons in general, mscRE5 / GABAergic neurons in general, mscRE8 / GABAergic neurons in general, eHGT_019h / Lamp5 neurons, eHGT_022h / Lamp5 and Vip neurons, eHGT_022m / Lamp5 and Vip neurons. neurons, eHGT_017h / Lamp5, Vip and Sst neurons, eHGT_17m / Lamp5, Vip and Sst neurons, eHGT_079h / parvalbumin (Pvalb) neuronal cell type, eHGT_082h / Pvalb neuronal cell type and deep cerebellar nuclei cells, eHGT_086h / Pvalb neuronal cell type, eHGT_128h / Pvalb neuronal cell type, eHGT_140h / Pvalb neuronal cell type, eHGT_064h / Pvalb and Sst neuronal cell types, eHGT_023h / Pvalb cell type, L4 and L5 IT neurons, cerebellar Purkinje cells, and eHGT_359 / Pvalb cell type and cerebellar Purkinje cells. In certain embodiments, unless otherwise specified, the target cell type is a neocortical cell type.

[0014] Certain embodiments provide artificial expression constructs comprising features of the vectors described herein, including the vectors: AiP1146, AiP1113, AiP1147, AiP1147, AiP1013, AiP1012, CN1525, CN1528, CN1532, CN1621, CN1633, CN1259, CN2045, CN1255, CN1408, CN1258, CN1279, CN1253, and CN1274.

[0015] Aspects of the present disclosure will now be described with the following additional options and details: (i) artificial expression constructs and vectors for selective expression of genes in selected cell types; (ii) compositions for administration; (iii) cell lines comprising the artificial expression constructs; (iv) transgenic animals; (v) methods of use; (vi) kits and commercial packages; (vii) exemplary embodiments; (viii) experimental examples; and (ix) final paragraph.

[0016] (i) Artificial expression constructs and vectors for selective expression of genes in selected cell types. The artificial expression constructs disclosed herein include (i) an enhancer sequence that confers selective expression of a coding sequence in a target central nervous system cell type, (ii) the coding sequence to be expressed, and (iii) a promoter. The artificial expression constructs can also include other regulatory elements if necessary or beneficial.

[0017] In certain embodiments, an "enhancer" or "enhancer element" is a cis-acting sequence that increases the level of transcription associated with a promoter, can function in either orientation relative to the promoter and the coding sequence to be transcribed, and can be located upstream or downstream relative to the promoter or the coding sequence to be transcribed. There are art-recognized methods and techniques for measuring the function of enhancer element sequences. Specific examples of enhancer sequences utilized within the artificial expression constructs disclosed herein include Grik1_enhGad2-1, Grik1_enhGad2-2, mscRE5, mscRE8, eHGT_019h, eHGT_022h, eHGT_022m, eHGT_017h, eHGT_17m, eHGT_079h, eHGT_082h, eHGT_086h, eHGT_128h, eHGT_140h, eHGT_064h, eHGT_023h, and eHGT_359.

[0018] In certain embodiments, the target central nervous system cell type enhancer is an enhancer that is uniquely or primarily utilized by the target central nervous system cell type, that enhances expression of a gene in the target central nervous system cell type but does not substantially direct expression of the gene in other non-target cell types, and thus has neural-specific transcriptional activity.

[0019] A product of a coding sequence is preferentially expressed in a selected cell type when the coding sequence is selectively expressed in the selected cell and substantially not expressed in other cell types. In certain embodiments, preferential expression is greater than 50% expression compared to a reference cell type, greater than 60% expression compared to a reference cell type, greater than 70% expression compared to a reference cell type, greater than 80% expression compared to a reference cell type, or greater than 90% expression compared to a reference cell type. In certain embodiments, the reference cell type refers to a non-target cell. The non-target cell may be in the same anatomical structure as the target cell and / or may project to a common anatomical region. In certain embodiments, the reference cell type is in an anatomical structure adjacent to the anatomical structure containing the target cell type. In certain embodiments, the reference cell type is a non-target GABAergic cell that has a gene expression profile different from that of the target cell.

[0020] In certain embodiments, the product of the coding sequence may be expressed at low levels in unselected cell types, for example, at less than 1%, or 1%, 2%, 3%, 5%, 10%, 15%, or 20% of the level at which the product is expressed in selected cells. In certain embodiments, the target central nervous system cell type is the only cell type that expresses the correct combination of transcription factors that bind to the enhancers disclosed herein to drive gene expression. Thus, in certain embodiments, expression occurs only within the target cell type.

[0021] In certain embodiments, target cell types (e.g., neural, neuronal, and / or non-neuronal) can be identified based on transcriptional profiles as described in Tasic et al., Nature 563, 72-78 (2018) and Hodge et al., Nature 573, 61-68 (2019). For reference, the following description of neural cell types and distinguishing characteristics is also provided.

[0022] Neocortical GABAergic subclasses: All: express the GABA synthesis genes Gad1 / GAD1 and Gad2 / GAD2.

[0023] · Lamp5, Sncg, Serpinf1 and Vip: developmentally derived from neuronal precursor cells in the caudal ganglionic eminence (CGE) or preoptic area (POA).

[0024] · Sst and Pvalb: Developmentally derived from neuronal precursor cells in the medial ganglionic eminence (MGE).

[0025] Lamp5: Found in many neocortical layers, especially the upper layers (L1-L2 / 3), and mainly has neuroglial and single bouquet morphology.

[0026] Sncg: Found in many neocortical layers and has molecular overlap with Lamp5 and Vip cells, but expression of Lamp5 or Vip is inconsistent and expression of Sncg is more consistent.

[0027] Serpinf1: Found in many neocortical layers and has molecular overlap with Sncg and Vip cells, but expression of Sncg or Vip is inconsistent and expression of Serpinf1 is more consistent.

[0028] Vip: Found in many neocortical layers, but particularly frequent in the upper layers (L1-L4), they highly express the neurotransmitter vasoactive intestinal peptide (Vip).

[0029] Sst: Found in many neocortical layers, but especially frequent in the lower layers (L5-L6). They highly express the neurotransmitter somatostatin (Sst) and frequently block dendritic input to postsynaptic neurons. This subclass includes sleep-active Sst Chodl neurons (which also express Nos1 and Tacr1), which are very distinct from other Sst neurons but express several shared marker genes, including Sst. In humans, Sst gene expression is often detected in Lamp5+ cells in layer 1.

[0030] Pvalb: Found in many neocortical layers, but particularly frequent in the lower layers (L5-L6). They highly express the calcium-binding protein parvalbumin (Pvalb), express the neuropeptide Tac1, and frequently inhibit the output of postsynaptic neurons. Most fast-spiking GABAergic cells strongly express Pvalb. This subclass includes chandelier cells, which have a distinct chandelier-like morphology and express the markers Cpne5 and Vipr2 in mice and NOG and UNC5B in humans.

[0031] Meis2: A distinct subclass defined by a single neocortical GABAergic phenotype that expresses the Meis2 gene and does not express several other genes expressed by all other neocortical GABAergic phenotypes (e.g., Thy1 and Scn2b). This phenotype is found in L6b and subcortical white matter.

[0032] Neocortical glutamatergic subclasses: All: express the glutamate transmitters Slc17a6 and / or Slc17a7. They all express Snap25, lack expression of Gad1 / Gad2, and lack expression of Slc1A3.

[0033] · L2 / 3 IT: Predominantly present in layer 2 / 3, with primarily intratelencephalic (corticocortical) projections.

[0034] · L4 IT: Predominantly present in layer 4, with primarily regional or intratelencephalic (corticocortical) projections.

[0035] L5 IT: Predominantly located in layer 5, with primarily intratelencephalic (corticocortical) projections. Also called L5a.

[0036] L5 PT: Predominantly located in layer 5, with primarily corticosubcortical (pyramidal or corticofugal) projections. Also called L5b or L5 CF (corticofugal) or L5 ET (extratelencephalic). This subclass includes cells located in the primary motor cortex and adjacent areas that are corticospinal projection neurons, which are associated with motor neuron / movement disorders such as ALS. This subclass includes thick-tufted pyramidal neurons, which contain unique cell types found only in specialized regions, such as Betz cells, Meynert cells, and von Economo cells.

[0037] L5 NPs: Present mainly in layer 5, with projections mainly nearby.

[0038] L6 CT: Predominantly located in layer 6, with primarily corticothalamic projections.

[0039] L6 IT: Predominantly located in layer 6, with primarily intratelencephalic (corticocortical) projections. Included in this subclass are the L6 IT Car3 cells, which are very similar to the intracortical projection cells of the claustrum.

[0040] · L6b: Located mainly in the neocortical subplate (L6b), with local (near the cell body) projections and some corticocortical projections from VISp to the anterior cingulate, as well as corticosubcortical projections to the thalamus.

[0041] · Cajal-Retzius cells, a distinct subclass defined by a single type of CR:L1, express distinct molecular markers Lhx5 and Trp73.

[0042] Cerebellar Purkinje cells: large GABAergic neurons that are the only projection neurons and the only output from the cerebellum. Their cell bodies form a single layer, the so-called "Purkinje cell layer," and they express parvalbumin.

[0043] Deep cerebellar nucleus neurons: neurons located in the deep cerebellar nucleus structures. These include excitatory cells and GABAergic cells that express the gene Pvalb.

[0044] Non-neuronal subclasses: Astrocytes: Neuroectodermal-derived glial cells that express the markers Aqp4 and often GFAP, but not the neuronal marker SNAP25. They can have a distinct star-shaped morphology and are involved in metabolic support of other cells in the brain. Multiple astrocyte morphologies are observed in mice and humans.

[0045] Oligodendrocytes: Neuroectoderm-derived glial cells that express the marker Sox10. This category includes oligodendrocyte precursor cells (OPCs). Oligodendrocytes are a subclass primarily involved in myelination of neurons.

[0046] · VLMC: Vascular leptomeningeal cells (VLMC) are part of the meninges that surround the outer layer of the cortex and express the marker genes Lum and Col1a1.

[0047] Pericytes: Blood vessel-associated cells that express the marker genes Kcnj8 and Abcc9. Pericytes surround endothelial cells and are important in regulating capillary blood flow and are involved in blood-brain barrier permeability.

[0048] SMC: Specialized smooth muscle cells, which are blood vessel-associated cells that express the marker gene Acta2. SMCs line the cerebral arterioles and are involved in blood-brain barrier permeability.

[0049] Endothelial cells: cells that line the blood vessels in the brain. Endothelial cells express the markers Tek and PDGF-B.

[0050] Microglia: Brain-resident macrophages are hematopoietic-derived immune cells, and perivascular macrophages (PVMs) may be transiently associated with brain tissue or may be included as a by-product of brain dissection procedures. Microglia are known to express Cx3cr1, Tmem119, and PTPRC (CD45).

[0051] In certain embodiments, the coding sequence is a heterologous coding sequence that encodes an effector element. An effector element is a sequence that is expressed to achieve a desired effect and actually achieves the desired effect. Examples of effector elements include reporter genes / proteins and functional genes / proteins.

[0052] Exemplary reporter genes / proteins include those expressed by Addgene ID#83894 (pAAV-hDlx-Flex-dTomato-Fishell_7), 83895 (pAAV-hDlx-Flex-GFP-Fishell_6), 83896 (pAAV-hDlx-GiDREADD-dTomato-Fishell-5), 83898 (pAAV-mDlx-ChR2-mCherry-Fishell-3), 83899 (pAAV-mDlx-GCaMP6f-Fishell-2), 83900 (pAAV-mDlx-GFP-Fishell-1), and 89897 (pcDNA3-FLAG-mTET2(N500)).Exemplary reporter genes include blue fluorescent proteins (e.g., eBFP, eBFP2, Azurite, mKalama1, GFPuv, Sapphire, T-sapphire), cyan fluorescent proteins (e.g., eCFP, Cerulean, CyPet, AmCyanl, Midoriishi-Cyan, mTurquoise), green fluorescent proteins (e.g., GFP, GFP-2, tagGFP, turboGFP, EGFP, Emerald, Azami Green, Monomeric Azami Green (mAzamigreen), CopGFP, AceGFP, avGFP, ZsGreenl, Oregon Green™ (Thermo Fisher Scientific)), luciferase, orange fluorescent proteins (mOrange, mKO, Kusabira-Orange, Monomeric Fluorescent Protein), among others, which encode expressible fluorescent proteins or expressible biotin. Examples of fluorescent proteins include Kusabira-Orange, mTangerine, tdTomato, and dTomato), red fluorescent proteins (mKate, mKate2, mPlum, DsRed monomer, mCherry, mRuby, mRFP1, DsRed-Express, DsRed2, DsRed-Monomer, HcRed-Tandem, HcRedl, AsRed2, eqFP611, mRaspberry, mStrawberry, Jred, and Texas Red™ (Thermo Fisher Scientific), far-red fluorescent proteins (e.g., mPlum and mNeptune), yellow fluorescent proteins (e.g., YFP, eYFP, Citrine, SYFP2, Venus, YPet, PhiYFP, and ZsYellowl), and tandem conjugates.

[0053] GFP, consisting of 238 amino acids (26.9 kDa), was originally isolated from the jellyfish Aequorea victoria / Aequorea aequorea / Aequorea forskalea, which fluoresces green when exposed to blue light. The GFP from A. victoria has a major excitation peak at 395 nm and a minor excitation peak at 475 nm. Its emission peak is at 509 nm, in the low-green portion of the visible spectrum. The GFP from the sea pansy Renilla reniformis has a single major excitation peak at 498 nm. Due to its potential for widespread use and the evolving needs of researchers, many different variants of GFP have been genetically engineered. The first major improvement was a single point mutation (S65T) reported by Roger Tsien in Nature in 1995. This mutation dramatically improved the spectral properties of GFP, resulting in increased fluorescence, photostability, and a shift in the major excitation peak to 488 nm while maintaining peak emission at 509 nm. Addition of the 37°C folding efficiency (F64L) point mutant to this scaffold yielded enhanced GFP (EGFP), whose optical cross section, also known as 9.13 × 10 m 2 It has an extinction coefficient (denoted ε) of 55,000 L / (mol·cm) / mol, also quoted as 55,000 L / (mol·cm). Superfolder GFP, a series of mutations that allow GFP to fold and mature rapidly even when fused to a fully folded peptide, was reported in 2006.

[0054] "Yellow fluorescent protein" (YFP) is a genetic variant of green fluorescent protein derived from Aequorea victoria. Its excitation peak is 514 nm and its emission peak is 527 nm.

[0055] Exemplary functional molecules include functional ion transporters, cellular trafficking proteins, enzymes, transcription factors, neurotransmitters, calcium reporters, channelrhodopsins, guide RNAs, nucleases, or designer receptors activated exclusively by designer drugs (DREADDs).

[0056] Ion transporters are transmembrane proteins that mediate the transport of ions across cell membranes. These transporters are widespread across most cell types and are important for regulating cellular excitability and homeostasis. Ion transporters are involved in numerous cellular processes, such as action potentials, synaptic transmission, hormone secretion, and muscle contraction. Many important biological processes in living cells involve the transport of calcium (Ca) through such ion channels. 2+ ), potassium (K + ) and sodium (Na + In certain embodiments, ion transporters include voltage-gated sodium channels (e.g., SCN1A), potassium channels (e.g., KCNQ2), and calcium channels (e.g., CACNA1C).

[0057] Exemplary enzymes, transcription factors, receptors, membrane proteins, cellular transport proteins, signaling molecules and neurotransmitters include enzymes such as lactase, lipase, helicase, α-glucosidase, amylase, etc.; transcription factors such as SP1, AP-1, heat shock factor protein 1, C / EBP (CCAA-T / enhancer binding protein) and Oct-1; receptors such as transforming growth factor receptor β1, platelet-derived growth factor receptor, epidermal growth factor receptor, vascular endothelial growth factor receptor and interleukin-8 receptor α; membrane proteins, cellular transport proteins such as clathrin, dynamin, caveolin, Rab-4A and Rab-11A; signaling molecules such as nerve growth factor (NGF), platelet-derived growth factor (PDGF), transforming growth factor β (TGFβ), epidermal growth factor (EGF), GTPase and HRas; and neurotransmitters such as cocaine- and amphetamine-regulated transcripts, substance P, oxytocin and somatostatin.

[0058] In certain embodiments, the functional molecule comprises a reporter of neural function and state, such as a calcium reporter. Intracellular calcium concentration is an important predictor of numerous cellular activities, including neuronal activation, muscle cell contraction, and second messenger signaling. A highly sensitive and convenient technique for monitoring intracellular calcium levels relies on genetically encoded calcium indicators (GECIs). Among GECIs, a green fluorescent protein (GFP)-based calcium sensor called GCaMP is an efficient and widely used tool. GCaMP is formed by fusing M13 and calmodulin proteins to the N- and C-termini of circularly permuted GFP. Several GCaMPs produce distinct fluorescence emission spectra (Zhao et al., Science, 2011, 333(6051):1888-1891). Exemplary GECIs with green fluorescence include GCaMP3, GCaMP5G, GCaMP6s, GCaMP6m, GCaMP6f, jGCaMP7s, jGCaMP7c, jGCaMP7b, and jGCaMP7f. Additionally, GECIs with red fluorescence include jRGECO1a and jRGECO1b. AAV products containing GECIs are commercially available.For example, Vigene Biosciences offers AAV8-CAG-GCaMP3 (catalog number: BS4-CX3AAV8), AAV8-Syn-FLEX-GCaMP6s-WPRE (catalog number: BS1-NXSAAV8), AAV8-Syn-FLEX-GCaMP6s-WPRE (catalog number: BS1-NXSAAV8), AAV9-CAG-FLEX-GCaMP6m-WPRE (catalog number: BS2-CXMAAV9), AAV9-Syn-FLEX-jGCaMP7s-WPRE (catalog number: BS12-NXSAAV9), and AAV9-CAG-FLEX The company offers AAV products including AAV9-Syn-FLEX-jGCaMP7f-WPRE (Catalog No.: BS12-CXFAAV9), AAV9-Syn-FLEX-jGCaMP7b-WPRE (Catalog No.: BS12-NXBAAV9), AAV9-Syn-FLEX-jGCaMP7c-WPRE (Catalog No.: BS12-NXCAAV9), AAV9-Syn-FLEX-NES-jRGECO1a-WPRE (Catalog No.: BS8-NXAAAV9), and AAV8-Syn-FLEX-NES-jRCaMP1b-WPRE (Catalog No.: BS7-NXBAAV8).

[0059] In certain embodiments, the calcium reporter comprises a genetically encoded calcium indicator GECI, NTnC; a myosin light chain kinase, GFP, calmodulin chimera; the calcium indicator TN-XXL; a BRET-based autoluminescent calcium indicator; and / or the calcium indicator protein OeNL(Ca2+)-18u).

[0060] In certain embodiments, the functional molecule comprises a modulator of neuronal activity, such as channelrhodopsin (e.g., channelrhodopsin-1, channelrhodopsin-2, and their variants). Channelrhodopsins are a subfamily of retinylidene ion-channel proteins (rhodopsins) that function as light-activated ion channels. In addition to channelrhodopsin 1 (ChR1) and channelrhodopsin 2 (ChR2), several variants of channelrhodopsins have been developed. For example, Lin et al. (Biophys J, 2009, 96(5):1803-14) describe the creation of chimeras of the transmembrane domains of ChR1 and ChR2 in combination with site-directed mutagenesis. Zhang et al. (Nat Neurosci, 2008, 11(6):631-3) describe a red-shifted channelrhodopsin variant, VChR1. Other known channelrhodopsin mutants include ChR2 (Nagel et al., Proc Natl Acad Sci USA, 2003, 100(24):13940-5), ChR2 / H134R (Nagel, G., et al., Curr Biol, 2005, 15(24):2279-84), and ChD / ChEF / ChIEF (Lin, JY, et al., Biophys J, 2009, 96(5):1803-14), which are activated by blue light (470 nm) but are insensitive to orange / red light. Additional mutants are described in Lin, Experimental Physiology, 2010, 96.1:19-25 and Knopfel et al., The Journal of Neuroscience, 2010, 30(45):14998-15004.

[0061] In certain embodiments, functional molecules include DNA and RNA editing tools such as CRISPR / CAS (e.g., guide RNA and nucleases such as Cas, Cas9, or cpfl. Functional molecules can also include engineered Cpfl as described in US2018 / 0030425, US2016 / 0208243, WO / 2017 / 184768, and Zetsche et al. (2015) Cell 163:759-771, a single gRNA (see, e.g., Jinek et al. (2012) Science 337:816-821, Jinek et al. (2013) eLife 2:e00471, Segal (2013) eLife 2:e00563) or an editase, a guide RNA molecule, or a homologous recombination donor cassette.

[0062] Additional effector elements include Cre, iCre, dgCre, FlpO, and tTA2. iCre refers to codon-improved Cre. dgCre refers to a highly sensitive GFP / Cre recombinase fusion gene with an N-terminal fusion of the first 159 amino acids of the chromosomal dihydrofolate reductase gene (DHFR or folA) of Escherichia coli K-12 strain, which contains a G67S mutation and has been modified to also contain an R12Y / Y100I destabilization domain mutation. FlpO refers to a codon-optimized form of FLPe, which significantly increases protein expression and FRT recombination efficiency in mouse cells. Similar to the Cre / LoxP system, the FLP / FRT system is widely used for gene expression (and for generating conditional knockout mice mediated by the FLP / FRT system). tTA2 refers to the tetracycline transactivator.

[0063] Exemplary expressible elements are expression products that do not include effector elements, e.g., non-functional or defective proteins. In certain embodiments, expressible elements can provide a method for studying the effects of their functional counterparts. In certain embodiments, expressible elements are non-functional or defective based on engineered mutations that render them non-functional. In these aspects, non-expressible elements are as similar in structure as possible to their functional counterparts.

[0064] Exemplary self-cleaving peptides include 2A peptides, which result in the production of two proteins from a single mRNA. 2A sequences are short (e.g., 20 amino acids), allowing for more use in size-restricted constructs. Specific examples include P2A, T2A, E2A, and F2A. In certain embodiments, the artificial expression construct includes an internal ribosome entry site (IRES) sequence. The IRES allows ribosomes to initiate translation at a second internal site in the mRNA molecule, resulting in the production of two proteins from a single mRNA.

[0065] Coding sequences encoding the molecules (e.g., RNA, proteins) described herein can be obtained from publicly available databases and publications. Coding sequences can further contain various sequence polymorphisms, mutations, and / or sequence variants, where such changes do not affect the function of the encoded molecule. The terms "encode" or "encoding" refer to the property of a nucleic acid sequence, such as a vector, plasmid, gene, cDNA, mRNA, etc., that serves as a template for the synthesis of another molecule, such as a protein.

[0066] The term "gene" can include not only the coding sequence but also regulatory regions such as promoters, enhancers, insulators, and / or post-regulatory elements such as termination regions. The term can further include all introns and other DNA sequences spliced ​​from the mRNA transcript, along with variants resulting from alternative splice sites. The sequence can also include degenerate codons of the reference sequence or sequences that may be introduced to provide codon preference in a particular organism or cell type.

[0067] Promoters may include general promoters, tissue-specific promoters, cell-specific promoters, and / or cytoplasm-specific promoters. Promoters may include strong promoters, weak promoters, constitutive expression promoters, and / or inducible promoters. Inducible promoters induce expression in response to specific conditions, signals, or cellular events. For example, a promoter may be an inducible promoter that requires a specific ligand, small molecule, transcription factor, or hormone protein to effect transcription from the promoter. Specific examples of promoters include minBglobin, CMV, minCMV, and mutant minCMV. * (minCMV * is minCMV with the SacI restriction site removed), minRho, minRho * (minRho * Examples of such promoters include the SV40 immediate early promoter, the Hsp68 minimal promoter (proHSP68), and the Rous sarcoma virus (RSV) long terminal repeat (LTR) promoter. Minimal promoters do not have the activity to drive gene expression by themselves, but can be activated to drive gene expression when linked to a proximal enhancer element.

[0068] In certain embodiments, the expression construct is provided within a vector. The term vector refers to a nucleic acid molecule that can transfer or transport another nucleic acid molecule, such as an expression construct. The transferred nucleic acid is generally linked, e.g., inserted, into the vector nucleic acid molecule. The vector may contain sequences that direct autonomous replication within the cell or may contain sequences that allow integration into host cell DNA. Useful vectors include, for example, plasmids (e.g., DNA or RNA plasmids), transposons, cosmids, bacterial artificial chromosomes, and viral vectors.

[0069] The term viral vector is broadly used to refer to nucleic acid molecules that contain virus-derived components that facilitate the transfer and expression of non-naturally occurring nucleic acid molecules in cells. The term adeno-associated viral vector refers to a viral vector or plasmid that contains structural and functional genetic elements, or portions thereof, primarily derived from AAV. The term "retroviral vector" refers to a viral vector or plasmid that contains structural and functional genetic elements, or portions thereof, primarily derived from retroviruses. The term "lentiviral vector" refers to a viral vector or plasmid that contains structural and functional genetic elements, or portions thereof, primarily derived from lentiviruses, etc. The term "hybrid vector" refers to a vector that contains structural and / or functional genetic elements derived from multiple virus types.

[0070] Adenoviral vectors refer to constructs containing sufficient adenoviral sequences to (a) support the packaging of an expression construct and (b) express a coding sequence cloned therein in either the sense or antisense orientation. Recombinant adenoviral vectors contain genetically engineered forms of adenovirus. Knowledge of the genetic organization of adenovirus, a 36 kb linear, double-stranded DNA virus, allows for the replacement of large segments of adenoviral DNA with foreign sequences up to 7 kb in size. In contrast to retroviruses, adenoviral DNA can replicate in an episomal manner without potential genotoxicity, so adenoviral infection of host cells does not result in chromosomal integration. Adenoviruses are also structurally stable, and no genome rearrangements have been detected after extensive amplification.

[0071] Adenoviruses are particularly suitable for use as gene transfer vectors due to their medium-sized genome, ease of manipulation, high titer, wide target cell range, and high infectivity. Both ends of the viral genome contain 100-200 base pair inverted repeats (ITRs), which are cis-receptors necessary for viral DNA replication and packaging. The early (E) and late (L) regions of the genome contain distinct transcription units that are separated by the initiation of viral DNA replication. The E1 region (E1A and E1B) encodes proteins involved in regulating the transcription of the viral genome and several cellular genes. Expression of the E2 region (E2A and E2B) results in the synthesis of proteins for viral DNA replication. These proteins are involved in DNA replication, late gene expression, and host cell shutoff. The products of the late genes, including most of the viral capsid proteins, are expressed only after significant processing of a single primary transcript driven by the major late promoter (MLP). MLP is particularly efficient at late stages of infection, and all mRNAs generated from this promoter have a 5'-tripartite leader (TPL) sequence, making it a translation-friendly promoter.

[0072] Other than the requirement that the adenoviral vector be replication-deficient, or at least conditionally defective, the nature of the adenoviral vector is not believed to be critical to the successful practice of certain embodiments disclosed herein. The adenovirus may be of any of the 42 different known serotypes or subgroups A-F. In certain embodiments, adenovirus type 5 of subgroup C is the preferred starting material for obtaining a conditional replication-deficient adenoviral vector for use in certain embodiments, as adenovirus type 5 is the human adenovirus for which the most biochemical and genetic information is known and which has historically been used for most constructs using adenovirus as a vector.

[0073] As shown, typical vectors are replication-defective and do not have the adenovirus E1 region. Therefore, it will be most convenient to introduce a polynucleotide encoding a gene of interest into the position where the E1 coding sequence has been deleted. However, the insertion position of the construct within the adenovirus sequence is not critical. A polynucleotide encoding a gene of interest can also be inserted into the E3 region of an E3 replacement vector, or into the E4 region where a helper cell line or helper virus complements the E4 deficiency.

[0074] Adeno-associated virus (AAV) is a parvovirus found as a contaminant in adenovirus stocks. It is a ubiquitous virus not associated with any disease (antibodies are present in 85% of the US human population). It is also classified as a dependovirus because its replication depends on the presence of a helper virus, such as adenovirus. Various serotypes have been isolated, of which AAV-2 is the best characterized. AAVs have single-stranded linear DNA encapsidated by capsid proteins VP1, VP2, and VP3 to form icosahedral virions 20–24 nm in diameter.

[0075] AAV DNA is 4.7 kilobases long. It contains two open reading frames flanked by two ITRs. The AAV genome contains two major genes, rep and cap. The rep gene encodes proteins involved in viral replication, while cap encodes the capsid proteins VP1-VP3. Each ITR forms a T-shaped hairpin structure. These terminal repeats are the only AAV cis-stimulating elements essential for chromosomal integration. Therefore, AAV can be used as a vector in which all viral coding sequences have been removed and replaced with a cassette of delivery genes. Three AAV viral promoters have been identified and named p5, p19, and p40 according to their map locations. Transcription from p5 and p19 leads to the production of the rep protein, while transcription from p40 produces the capsid protein.

[0076] AAVs are prominent for use within the present disclosure due to their excellent safety profile and the ability to tailor their capsids and genomes to allow expression in selected cell populations. scAAV refers to self-complementary AAV. pAAV refers to plasmid adeno-associated virus. rAAV refers to recombinant adeno-associated virus.

[0077] Other viral vectors can also be used, such as those derived from viruses such as vaccinia virus, poliovirus, and herpesvirus, which offer several attractive features in a variety of mammalian cells.

[0078] Retroviruses are common tools for gene delivery. "Retrovirus" refers to an RNA virus that reverse-transcribes its genomic RNA into a linear, double-stranded DNA copy and then covalently integrates the genomic DNA into the host genome. Once the virus is integrated into the host genome, it is called a "provirus." The provirus serves as a template for RNA polymerase II, directing the expression of RNA molecules that encode the structural proteins and enzymes necessary to produce new virus particles.

[0079] Exemplary retroviruses suitable for use in certain embodiments include Moloney murine leukemia virus (M-MuLV), Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), mouse mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Friend murine leukemia virus, murine stem cell virus (MSCV), Rous sarcoma virus (RSV), and lentiviruses.

[0080] "Lentivirus" refers to a group (or genus) of complex retroviruses. Exemplary lentiviruses include HIV (human immunodeficiency viruses, including HIV types 1 and 2), visna-maedi virus (VMV), caprine arthritis-encephalitis virus (CAEV), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV), and simian immunodeficiency virus (SIV). In certain embodiments, an HIV-based vector backbone (i.e., HIV cis-acting sequence elements) can be used.

[0081] Enhanced safety for the use of some vectors can be provided by replacing the U3 region of the 5' LTR with a heterologous promoter to drive transcription of the viral genome during viral particle production. Examples of heterologous promoters that can be used for this purpose include the viral simian virus 40 (SV40) (e.g., early or late), cytomegalovirus (CMV) (e.g., immediate), Moloney murine leukemia virus (MoMLV), Rous sarcoma virus (RSV), and herpes simplex virus (HSV) (thymidine kinase) promoters. Typical promoters are capable of driving high levels of transcription in a Tat-independent manner. This replacement reduces the possibility of producing replication-competent virus by recombination due to the absence of an intact U3 sequence in the viral production system. In certain embodiments, heterologous promoters have the added advantage of controlling the manner in which the viral genome is transcribed. For example, heterologous promoters can be inducible, such that transcription of all or part of the viral genome occurs only in the presence of an inducer. Inducers include one or more compounds or physiological conditions, such as temperature or pH, under which host cells are cultured.

[0082] In certain embodiments, the viral vector comprises a TAR element. The term "TAR" refers to the "transactivation response" gene element located in the R region of lentiviral LTR. This element interacts with the lentiviral transactivator (tat) gene element to enhance viral replication. However, this element is not required in embodiments where the U3 region of 5'LTR is replaced by a heterologous promoter.

[0083] "R region" refers to the region within a retroviral LTR that begins at the start of the capping group (i.e., the start of transcription) and ends just before the start of the poly(A) tract. The R region is also defined as being flanked by the U3 and U5 regions. The R region serves to allow the transfer of nascent DNA from one end of the genome to the other during reverse transcription.

[0084] In certain embodiments, expression of heterologous sequences in viral vectors is increased by incorporating posttranscriptional regulatory elements, efficient polyadenylation sites, and, optionally, transcription termination signals into the vector. Various posttranscriptional regulatory elements can increase expression of heterologous nucleic acids. Examples include the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE, Zufferey et al., 1999, J. Virol., 73:2886), the posttranscriptional regulatory element (HPRE) present in hepatitis B virus (Smith et al., Nucleic Acids Res. 26(21):4818-4827, 1998), (Liu et al., 1995, Genes Dev., 9:1766), and the like. In certain embodiments, the vector comprises a posttranscriptional regulatory element such as a WPRE or HPRE. In certain embodiments, the vector lacks or does not comprise a posttranscriptional regulatory element such as a WPRE or HPRE.

[0085] Elements that direct efficient termination and polyadenylation of heterologous nucleic acid transcripts can increase heterologous gene expression. Transcription termination signals are generally found downstream of polyadenylation signals. In certain embodiments, vectors contain a polyadenylation signal 3' from a polynucleotide encoding an expressed molecule (e.g., a protein). The term "poly(A) site" or "poly(A) sequence" refers to a DNA sequence that directs both the termination and polyadenylation of a nascent RNA transcript by RNA polymerase II. Polyadenylation sequences can promote mRNA stability by adding a poly(A) tail to the 3' end of the coding sequence, thereby contributing to improved translation efficiency. Certain embodiments may utilize BGHpA or SV40pA. In certain embodiments, preferred expression constructs contain terminator elements. These elements help increase transcript levels and minimize readthrough from the construct to other plasmid sequences.

[0086] In certain embodiments, the viral vector further comprises one or more insulator elements. The insulator elements may help protect the viral vector expression sequence, e.g., effector element or expressible element, from integration site effects, which are mediated by cis-acting elements present in genomic DNA and may result in deregulated expression of the imported sequence (i.e., position effects; see, e.g., Burgess-Beusse et al., PNAS., USA, 99:16433, 2002 and Zhan et al., Hum. Genet., 109:471, 2001). In certain embodiments, the viral import vector comprises one or more insulator elements in the 3' LTR, and when the provirus integrates into the host genome, the provirus contains one or more insulator elements in both the 5' LTR and the 3' LTR by replicating the 3' LTR. Insulators suitable for use in certain embodiments include the chicken β-globin insulator (see Chung et al., Cell 74:505, 1993; Chung et al., PNAS USA 94:575, 1997; and Bell et al., Cell 98:387, 1999), the SP10 insulator (Abhyankar et al., JBC 282:36143, 2007), or other small CTCF recognition sequences that function as enhancer-blocking insulators (Liu et al., Nature Biotechnology, 33:198, 2015).

[0087] Beyond the foregoing description, a wide range of suitable expression vector types is known to those skilled in the art. These can include commercially available expression vectors designed for general recombinant procedures, such as plasmids containing one or more reporter genes and the regulatory elements necessary for reporter gene expression in cells. Numerous vectors are commercially available, for example, from Invitrogen, Stratagene, Clontech, etc., and are described in numerous related guides. In certain embodiments, suitable expression vectors include any plasmid, cosmid, or phage construct capable of supporting the expression of an encoded gene in mammalian cells, such as the pUC or Bluescript plasmid...

Claims

1. 1. An artificial expression construct comprising: (i) an enhancer selected from eHGT_140h, Grik1_enhGad2-1, Grik1_enhGad2-2, mscRE5, mscRE8, eHGT_019h, eHGT_022h, eHGT_022m, eHGT_017h, eHGT_17m, eHGT_079h, eHGT_082h, eHGT_086h, eHGT_128h, eHGT_064h, eHGT_023h and eHGT_359; (ii) a promoter; and (iii) a heterologous coding sequence.

2. 2. The artificial expression construct of claim 1, wherein the heterologous coding sequence encodes an effector element or an expressible element.

3. 3. The artificial expression construct of claim 2, wherein the effector element comprises a reporter protein or a functional molecule.

4. 4. The artificial expression construct of claim 3, wherein the reporter protein comprises a fluorescent protein.

5. 4. The artificial expression construct of claim 3, wherein the functional molecule comprises a functional ion transporter, an enzyme, a transcription factor, a receptor, a membrane protein, a cellular trafficking protein, a signaling molecule, a neurotransmitter, a calcium reporter, a channelrhodopsin, a CRISPR / CAS molecule, an editase, a guide RNA molecule, a homologous recombination donor cassette, or a designer receptor that is exclusively activated by a designer drug (DREADD).

6. 3. The artificial expression construct of claim 2, wherein the expressible element comprises a non-functional molecule.

7. 7. The artificial expression construct of claim 6, wherein the non-functional molecule comprises a non-functional ion transporter, an enzyme, a transcription factor, a receptor, a membrane protein, a cellular trafficking protein, a signaling molecule, a neurotransmitter, a calcium reporter, a channelrhodopsin, a CRISPR / CAS molecule, an editase, a guide RNA molecule, a homologous recombination donor cassette, or a DREADD.

8. 2. The artificial expression construct of claim 1, wherein the artificial expression construct is associated with a capsid that crosses the blood-brain barrier.

9. 9. The artificial expression construct of claim 8, wherein the capsid comprises PHP.eB, AAV-BR1, AAV-PHP.S, AAV-PHP.B, or AAV-PPS.

10. 2. The artificial expression construct of claim 1, wherein the artificial expression construct comprises or encodes a skipping element.

11. 11. The artificial expression construct of claim 10, wherein the skipping element comprises a 2A peptide or an internal ribosome entry site (IRES).

12. 12. The artificial expression construct of claim 11 , wherein the 2A peptide comprises T2A, P2A, E2A or F2A.

13. The artificial expression constructs were eHGT_140h, Grik1_enhGad2-1, Grik1_enhGad2-2, mscRE5, mscRE8, eHGT_019h, eHGT_022h, eHGT_022m, eHGT_017h, eHGT_17m, eHGT_079h, eHGT_082h, eHGT_086h, eHGT_128h, eHGT_064h, eHGT_023h and eHGT_359, AAV, scAAV, rAAV, minBglobin, CMV, minCMV, minRho, minRho ＊ 2. The artificial expression construct of claim 1, comprising or encoding a set of features selected from: a fluorescent protein, Cre, iCre, dgCre, FlpO, tTA2, SP10, WPRE, and / or BGHpA.

14. The artificial expression construct comprises: hsA2-eHGT_140h-minRho-SYFP2-WPRE3-BGHpA, Grik1_enhGad2-1-Hsp68-EGFP-WPRE3-BGHpA, Grik1_enhGad2-1-pBGmin-EGFP-WPRE3-BGHpA, Grik1_enhGad2-2-Hsp68-EGFP-WPRE3-BGHpA, mscRE5-pBGmin-EGFP-WPRE3-BGHpA, mscRE5-pBGmin-FlpO-WPRE3-BGHpA, mscRE8-pBGmin-EGFP-WPRE3-BGHpA, mscRE8-pBGmin-FlpO-WPRE3-BGHpA, scAAV-eHGT_019h-minBGlobin-SYFP2-WPRE3-BGHpA, scAAV-eHGT_022h-minBGlobin-SYFP2-WPRE3-BGHpA, scAAV-eHGT_022m-minBGlobin-SYFP2-WPRE3-BGHpA, scAAV-eHGT_017h-minBGlobin-SYFP2-WPRE3-BGHpA, hsA2-eHGT_079h-minRho-SYFP2-WPRE3-BGHpA, hsA2-eHGT_082h-minRho-SYFP2-WPRE3-BGHpA, hsA2-eHGT_086h-minRho-SYFP2-WPRE3-BGHpA, hsA2-eHGT_128h-minRho-SYFP2-WPRE3-BGHpA, eHGT_064h-minBglobin-SYFP2-WPRE3-BGHpA, or scAAV-eHGT_023h-minBGlobin-SYFP2-WPRE3-BGHpA 2. The artificial expression construct of claim 1, comprising or encoding a set of features selected from:

15. A vector comprising the artificial expression construct of claim 1.

16. The vector of claim 15 , wherein the vector comprises a viral vector.

17. The vector of claim 16 , wherein the viral vector comprises a recombinant adeno-associated viral (AAV) vector.

18. 1. An adeno-associated virus (AAV) vector comprising at least one heterologous coding sequence, wherein the heterologous coding sequence is under the transcriptional control of a promoter and an enhancer selected from eHGT_140h, Grik1_enhGad2-1, Grik1_enhGad2-2, mscRE5, mscRE8, eHGT_019h, eHGT_022h, eHGT_022m, eHGT_017h, eHGT_17m, eHGT_079h, eHGT_082h, eHGT_086h, eHGT_128h, eHGT_064h, eHGT_023h, and eHGT_359.

19. 19. The AAV vector of claim 18, wherein the heterologous coding sequence encodes an effector element or an expressible element.

20. The AAV vector of claim 19 , wherein the effector element comprises a reporter protein or a functional molecule.

21. The AAV vector of claim 20 , wherein the reporter protein comprises a fluorescent protein.

22. The AAV vector of claim 20, wherein the functional molecule comprises a functional ion transporter, an enzyme, a transcription factor, a receptor, a membrane protein, a cellular trafficking protein, a signaling molecule, a neurotransmitter, a calcium reporter, a channelrhodopsin, a CRISPR / CAS molecule, an editase, a guide RNA molecule, a homologous recombination donor cassette or a DREADD.

23. 20. The AAV vector of claim 19, wherein the expressible element comprises a non-functional molecule.

24. 24. The AAV vector of claim 23, wherein the nonfunctional molecule comprises a nonfunctional ion transporter, an enzyme, a transcription factor, a receptor, a membrane protein, a cellular trafficking protein, a signaling molecule, a neurotransmitter, a calcium reporter, a channelrhodopsin, a CRISPR / CAS molecule, an editase, a guide RNA molecule, a homologous recombination donor cassette, or a DREADD.

25. The AAV vector of claim 18, wherein the AAV vector is replication-competent.

26. A transgenic cell comprising an artificial expression construct according to claim 1 and / or a vector according to claim 18.

27. The transgenic cell of claim 26, wherein the transgenic cell is a GABAergic neuron.

28. 27. The transgenic cell of claim 26, wherein the transgenic cell is a parvalbumin (Pvalb) neuron, a lysosomal membrane protein 5 (Lamp5) neuron, a vasoactive intestinal polypeptide expressing (Vip) neuron, a somatostatin (Sst) neuron, a layer 4 (L4) intratelencephalic (IT) neuron, a layer 5 (L5) IT neuron, a deep cerebellar nucleus neuron or a cerebellar Purkinje cell.

29. 27. The transgenic cell of claim 26, wherein the transgenic cell is murine, human, or non-human primate.

30. A non-human transgenic animal comprising an artificial expression construct according to claim 1, a vector according to claim 18, and / or a transgenic cell according to claim 26.

31. The non-human transgenic animal of claim 30, wherein the non-human transgenic animal is a mouse or a non-human primate.

32. 27. An administrable composition comprising an artificial expression construct according to claim 1, a vector according to claim 18, and / or a transgenic cell according to claim 26.

33. A kit comprising an artificial expression construct according to claim 1, a vector according to claim 18, a transgenic cell according to claim 26, and / or a transgenic animal according to claim 30.

34. 34. A method for selectively expressing a gene in a neuronal population in vivo or in vitro, comprising providing an administrable composition of claim 32 to a sample or subject comprising said neuronal population in a sufficient dosage and for a sufficient period of time to selectively express said gene in said neuronal population.

35. 35. The method of claim 34, wherein the gene encodes an effector element or an expressible element.

36. 36. The method of claim 35, wherein the effector element comprises a reporter protein or a functional molecule.

37. 37. The method of claim 36, wherein the reporter protein comprises a fluorescent protein.

38. 37. The method of claim 36, wherein the functional molecule comprises a functional ion transporter, an enzyme, a transcription factor, a receptor, a membrane protein, a cellular trafficking protein, a signaling molecule, a neurotransmitter, a calcium reporter, a channelrhodopsin, a CRISPR / CAS molecule, an editase, a guide RNA molecule, a homologous recombination donor cassette, or a DREADD.

39. 36. The method of claim 35, wherein the expressible element comprises a non-functional molecule.

40. 40. The method of claim 39, wherein the non-functional molecule comprises a non-functional ion transporter, an enzyme, a transcription factor, a receptor, a membrane protein, a cellular trafficking protein, a signaling molecule, a neurotransmitter, a calcium reporter, a channelrhodopsin, a CRISPR / CAS molecule, an editase, a guide RNA molecule, a homologous recombination donor cassette, or a DREADD.

41. 35. The method of claim 34, wherein providing comprises pipetting.

42. 42. The method of claim 41, wherein the pipetting is on a brain slice.

43. 43. The method of claim 42, wherein the brain slice comprises GABAergic neurons.

44. 43. The method of claim 42, wherein the brain slice comprises Pvalb neurons, Lamp5 neurons, Vip neurons, Sst neurons, L4 IT neurons, L5 IT neurons, deep cerebellar nuclei neurons, and / or cerebellar Purkinje cells.

45. 43. The method of claim 42, wherein the brain slice is from a mouse, a human, or a non-human primate.

46. 35. The method of claim 34, wherein providing comprises administering to a living subject.

47. 47. The method of claim 46, wherein the living subject is a human, a non-human primate, or a mouse.

48. 47. The method of claim 46, wherein administering to a living subject is by injection.

49. 49. The method of claim 48, wherein the injection comprises intravenous injection, intraparenchymal injection into brain tissue, intracerebroventricular (ICV) injection, intracisternal (ICM) injection, or intrathecal injection.

50. CN1633, AiP1146, AiP1113, AiP1147, AiP1147, AiP1013, AiP1012, CN1525, CN1528, CN1532, CN1621, CN1259, CN2045, CN1255, CN1408, CN1258, CN1279, CN1253, or CN1274.

Images